Purpose To assess the effectiveness of anti-reflux treatment in gastroesophageal reflux disease patients classified according to esophagogastric junction morphology (Hill classification). Results A symptom score and endoscopic grading of gastrooesophageal flap valve appearance were determined in 49 symptomatic patients (female 26, male 23; mean age 49 years, range 21–76 years). Patients received 8 weeks of continuous rabeprazole at a daily dose of 20 mg and, upon symptom control, continued with on-demand treatment for 3 months. The mean symptom score at 8 weeks was significantly reduced in all groups. However, at the end of the on-demand therapy, patients with Hill grade IV had used more rabeprazole tablets than those in the two other groups (II: 10.86 ± 14.52, III: 14.73 ± 14.58, IV: 25.78 ± 15.85; P = 0.002). Conclusions Continuous treatment is effective in all groups of patients with reflux disease. Grading patients according to the gastroesophageal flap valve appearance is useful as a prognostic factor, especially when on-demand therapy is considered to be an option.
Cloud ML, Enas N, Humphries TJ et al (1998) Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose–response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43(5):993–1000. doi:10.1023/A:1018822532736PubMedCrossRefGoogle Scholar
Bour B, Staub JL, Chousterman M et al (2005) Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21(7):805–812. doi:10.1111/j.1365-2036.2005.02413.xPubMedCrossRefGoogle Scholar
Pace F, Tonini M, Pallotta S et al (2007) Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther 26(2):195–204PubMedCrossRefGoogle Scholar
Carlsson R, Dent J, Watts R et al (1998) Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10(2):119–124. doi:10.1097/00042737-199802000-00004PubMedCrossRefGoogle Scholar
Oberg S, Peters JH, DeMeester TR et al (1999) Endoscopic grading of the gastroesophageal valve in patients with symptoms of gastroesophageal reflux disease (GERD). Surg Endosc 13(12):1184–1188. doi:10.1007/PL00009617PubMedCrossRefGoogle Scholar
Ponce J, Arguello L, Bastida G et al (2004) On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 49(6):931–936. doi:10.1023/B:DDAS.0000034551.39324.c3PubMedCrossRefGoogle Scholar
Hungin AP, Rubin G, O’Flanagan H (1999) Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 49(443):463–464PubMedGoogle Scholar